Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 31, 2020 20:41 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., Jan. 31, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the closing of its upsized underwritten public offering of 9,000,000 shares of...
January 28, 2020 20:58 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 7,826,087 shares of its...
January 27, 2020 16:10 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Announces Proposed Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced that it intends to offer and sell shares of its common stock in an underwritten...
January 14, 2020 09:00 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Announces Broad Pipeline Progress Including Positive Results From Its LRRK2 Program for Parkinson’s Disease

LRRK2 inhibitor DNL201 Phase 1b demonstrated high levels of target and pathway engagement and improvement of lysosomal biomarkers in patients with Parkinson’s disease LRRK2 inhibitor DNL151 Phase 1...
November 06, 2019 16:30 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Reports Third Quarter 2019 Financial Results and Business Highlights

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for...
September 04, 2019 09:00 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL151 for Parkinson’s Disease and Launch of Its Engage Parkinson’s Website

Phase 1b study of DNL151 includes Parkinson’s disease patients with and without a genetic LRRK2 mutationEither DNL151 or DNL201 anticipated to be selected for potential registrational clinical trials...
August 06, 2019 16:30 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Reports Second Quarter 2019 Financial Results and Business Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for...
August 05, 2019 09:00 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Announces That Its Partner Sanofi has Commenced Dosing of DNL758 in a Phase 1 Study

Sanofi has commenced dosing of DNL758 in a Phase 1 healthy volunteer study.DNL758 is an investigational small molecule RIPK1 inhibitor that does not cross the blood-brain barrier, and is intended for...
June 11, 2019 09:00 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designation for DNL310, and Expands its Portfolio of Brain Penetrant Enzyme Replacement Programs

DNL310 on track to enter Phase 1/2 clinical study in Hunter Syndrome patients in 2020DNL310 utilizes Denali’s proprietary blood-brain barrier crossing enzyme transport vehicle (“ETV”) technologyTwo...
May 08, 2019 16:30 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Reports First Quarter 2019 Financial Results

SOUTH SAN FRANCISCO, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for...